- Gene expression profiling of imatinib and PD166326-resistant CML cell lines identifies Fyn as a gene associated with resistance to BCR-ABL inhibitors
[作者:Grosso, S; Puissant, A; Dufies, M; Colosetti, P; Jacquel, A; Lebrigand, K; Barbry, P; Deckert, M; Cassuto, JP; Mari, B; Auberger, P,期刊:Molecular Cancer Therapeutics, 页码:1924-1933 , 文章类型: Article,,卷期:2009年8-7]
- Imatinib is used to treat chronic myelogenous leukemia (CML), but resistance develops in all phases of this disease. The purpose of the present study was to identify the mode of resistance of newly derived imatinib-resis...
- Ligand, receptor, and cell type-dependent regulation of ABCA1 and ABCG1 mRNA in prostate cancer epithelial cells
[作者:Trasino, SE; Kim, YS; Wang, TTY,期刊:Molecular Cancer Therapeutics, 页码:1934-1945 , 文章类型: Article,,卷期:2009年8-7]
- Recent evidence suggests that the liver X receptor (LXR) is a potential anticancer target in prostate carcinoma. There is little characterization, however, of which of the two LXR isoforms, LXR alpha or LXR beta, regulat...
- D,L-Sulforaphane causes transcriptional repression of androgen receptor in human prostate cancer cells
[作者:Kim, SH; Singh, SV,期刊:Molecular Cancer Therapeutics, 页码:1946-1954 , 文章类型: Article,,卷期:2009年8-7]
- D,L-Sulforaphane (SFN), a synthetic analogue of cruciferous vegetable-derived L-isomer, inhibits the growth of human prostate cancer cells in culture and in vivo and retards cancer development in a transgenic mouse model...
- Folate-mediated intracellular drug delivery increases the anticancer efficacy of nanoparticulate formulation of arsenic trioxide
[作者:Chen, H; Ahn, R; Van den Bossche, J; Thompson, DH; O'Halloran, TV,期刊:Molecular Cancer Therapeutics, 页码:1955-1963 , 文章类型: Article,,卷期:2009年8-7]
- Arsenic trioxide (As2O3) is a frontline drug for treatment of acute promyelocytic leukemia and is in clinical trials for treatment of other malignancies, including multiple myeloma; however, efforts to expand clinical ut...
- Epigenetic mechanisms of irinotecan sensitivity in colorectal cancer cell lines
[作者:Crea, F; Giovannetti, E; Cortesi, F; Mey, V; Nannizzi, S; Ruiz, MIG; Ricciardi, S; Del Tacca, M; Peters, GJ; Danesi, R,期刊:Molecular Cancer Therapeutics, 页码:1964-1973 , 文章类型: Article,,卷期:2009年8-7]
- Irinotecan is a topoisomerase-I (Top-I) inhibitor used for the treatment of colorectal cancer. DNA demethylating agents, including 5-azacytidine (5-aza), display synergistic antitumor activity with several chemotherapy d...
- Effect of autophagy on multiple myeloma cell viability
[作者:Hoang, B; Benavides, A; Shi, YJ; Frost, P; Lichtenstein, A,期刊:Molecular Cancer Therapeutics, 页码:1974-1984 , 文章类型: Article,,卷期:2009年8-7]
- Because accumulation of potentially toxic malfolded protein may be extensive in immunoglobulin-producing multiple myeloma (MM) cells, we investigated the phenomenon of autophagy in myeloma, a physiologic process that can...
- Proteomic identification of aldo-keto reductase AKR1B10 induction after treatment of colorectal cancer cells with the proteasome inhibitor bortezomib
[作者:Loeffler-Ragg, J; Mueller, D; Gamerith, G; Auer, T; Skvortsov, S; Sarg, B; Skvortsova, I; Schmitz, KJ; Martin, HJ; Krugmann, J; Alakus, H; Maser, E; Menzel, J; Hilbe, W; Lindner, H; Schmid, KW; Zwierzina, H,期刊:Molecular Cancer Therapeutics, 页码:1995-2006 , 文章类型: Article,,卷期:2009年8-7]
- Targeting the ubiquitin-proteasome pathway with the proteasome inhibitor bortezomib has emerged as a promising approach for the treatment of several malignancies. The cellular and molecular effects of this agent on color...
- Base excision repair of reactive oxygen species-initiated 7,8-dihydro-8-oxo-2 '-deoxyguanosine inhibits the cytotoxicity of platinum anticancer drugs
[作者:Preston, TJ; Henderson, JT; McCallum, GP; Wells, PG,期刊:Molecular Cancer Therapeutics, 页码:2015-2026 , 文章类型: Article,,卷期:2009年8-7]
- Anticancer therapy with cisplatin and oxaliplatin is limited by toxicity and onset of tumor resistance. Both drugs form platinum-DNA cross-linked adducts, and cisplatin causes oxidative DNA damage including the 7,8-dihyd...
- The telomerase template antagonist GRN163L alters MDA-MB-231 breast cancer cell morphology, inhibits growth, and augments the effects of paclitaxel
[作者:Goldblatt, EM; Gentry, ER; Fox, MJ; Gryaznov, SM; Shen, CY; Herbert, BS,期刊:Molecular Cancer Therapeutics, 页码:2027-2035 , 文章类型: Article,,卷期:2009年8-7]
- Telomeres are repetitive (TTAGGG)(n) DNA sequences found at the end of chromosomes that protect the ends from recombination, end to end fusions, and recognition as damaged DNA. Telomerase activity can be detected in 85% ...
- Biological properties of potent inhibitors of class I phosphatidylinositide 3-kinases: from PI-103 through PI-540, PI-620 to the oral agent GDC-0941
[作者:Raynaud, FI; Eccles, SA; Patel, S; Alix, S; Box, G; Chuckowree, I; Folkes, A; Gowan, S; Brandon, AD; Di Stefano, F; Hayes, A; Henley, AT; Lensun, L; Pergl-Wilson, G; Robson, A; Saghir, N; Zhyvoloup, A; McDonald, E; Sheldrake, P; Shuttleworth, S; Valenti, M; Wan, NC; Clarke, PA; Workman, P,期刊:Molecular Cancer Therapeutics, 页码:1725-1738 , 文章类型: Article,,卷期:2009年8-7]
- The phosphatidylinositide 3-kinase pathway is frequently deregulated in human cancers and inhibitors offer considerable therapeutic potential. We previously described the promising tricyclic pyridofuropyrimidine lead and...
- Oncogenic transformation confers a selective susceptibility to the combined suppression of the proteasome and autophagy
[作者:Ding, WX; Ni, HM; Gao, WT; Chen, XY; Kang, JH; Stolz, DB; Liu, JS; Yin, XM,期刊:Molecular Cancer Therapeutics, 页码:2036-2045 , 文章类型: Article,,卷期:2009年8-7]
- The proteasome and the autophagy systems are two evolutionarily conserved mechanisms for degrading intracellular materials. They are functionally coupled and suppression of the proteasome promotes autophagy. Although sup...
- Determinants for the efficiency of anticancer drugs targeting either Aurora-A or Aurora-B kinases in human colon carcinoma cells
[作者:Kaestner, P; Stolz, A; Bastians, H,期刊:Molecular Cancer Therapeutics, 页码:2046-2056 , 文章类型: Article,,卷期:2009年8-7]
- The mitotic Aurora kinases, including Aurora-A and Aurora-B, are attractive novel targets for anticancer therapy, and inhibitory drugs have been developed that are currently undergoing clinical trials. However, the molec...
- Narciclasine, a plant growth modulator, activates Rho and stress fibers in glioblastoma cells
[作者:Lefranc, F; Sauvage, S; Van Goietsenoven, G; Megalizzi, V; Lamoral-Theys, D; Debeir, O; Spiegl-Kreinecker, S; Berger, W; Mathieu, V; Decaestecker, C; Kiss, R,期刊:Molecular Cancer Therapeutics, 页码:1739-1750 , 文章类型: Article,,卷期:2009年8-7]
- Cell motility and resistance to apoptosis characterize glioblastoma multiforme growth and malignancy. Narciclasine, a plant growth modulator, could represent a powerful new weapon targeting the Achilles' heel of glioblas...
|